0
BioNTech SE Banner Image

BioNTech SE

  • Ticker BNTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BioNTech SE Logo Image
  • 1001-5000 Employees
  • Based in Mainz, Germany
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-basedMore therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
REPORT RATINGS
4.8 / 5.0 (54)

BioNTech SE reports have an aggregate usefulness score of 4.8 based on 54 reviews.

BioNTech SE

Most Recent Annual Report

BioNTech SE
MOST RECENT 2023 Annual Report

Older/Archived Annual Reports

BioNTech SE Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!